LABORATORY CORPORATION OF AMERICA HOLDINGS Financials Laboratory Corporation of America Holdings
Equities
LH
US50540R4092
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 198.4 USD | +0.03% |
|
-1.53% | -12.71% |
| Apr. 26 | Baird Adjusts Laboratory Corp of America Holdings' Price Target to $244 From $255 | MT |
| Apr. 26 | Barclays Adjusts Price Target on Laboratory Corp of America Holdings to $213 From $234 | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 16,426 | 19,826 | 30,070 | 20,864 | 19,297 | 16,725 | - | - |
| Enterprise Value (EV) 1 | 22,393 | 24,301 | 34,110 | 25,774 | 23,815 | 21,542 | 20,704 | 20,316 |
| P/E ratio | 20.3 x | 12.8 x | 12.9 x | 16.9 x | 47.6 x | 17 x | 15.2 x | 13.6 x |
| Yield | - | - | - | - | - | 1.45% | 1.5% | 1.53% |
| Capitalization / Revenue | 1.42 x | 1.42 x | 1.87 x | 1.4 x | 1.59 x | 1.31 x | 1.25 x | 1.19 x |
| EV / Revenue | 1.94 x | 1.74 x | 2.12 x | 1.73 x | 1.96 x | 1.68 x | 1.55 x | 1.45 x |
| EV / EBITDA | 11 x | 6.6 x | 8.11 x | 8.82 x | 11.5 x | 9.75 x | 8.8 x | 8.16 x |
| EV / FCF | 21.4 x | 13.9 x | 12.9 x | 17.5 x | 27.2 x | 20.1 x | 15.8 x | 13.8 x |
| FCF Yield | 4.66% | 7.22% | 7.77% | 5.72% | 3.67% | 4.97% | 6.32% | 7.24% |
| Price to Book | 2.17 x | 2.12 x | 2.85 x | 2.06 x | 2.42 x | 2.04 x | 1.84 x | 1.69 x |
| Nbr of stocks (in thousands) | 97,100 | 97,400 | 95,700 | 88,600 | 84,900 | 84,300 | - | - |
| Reference price 2 | 169.2 | 203.6 | 314.2 | 235.5 | 227.3 | 198.4 | 198.4 | 198.4 |
| Announcement Date | 2/13/20 | 2/11/21 | 2/10/22 | 2/16/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 11,555 | 13,978 | 16,121 | 14,877 | 12,162 | 12,792 | 13,397 | 14,059 |
| EBITDA 1 | 2,045 | 3,681 | 4,207 | 2,924 | 2,072 | 2,209 | 2,352 | 2,491 |
| EBIT 1 | 1,711 | 3,332 | 3,831 | 2,549 | 1,715 | 1,835 | 1,975 | 2,131 |
| Operating Margin | 14.81% | 23.84% | 23.76% | 17.13% | 14.1% | 14.35% | 14.74% | 15.16% |
| Earnings before Tax (EBT) 1 | 1,105 | 2,219 | 3,127 | 1,583 | 568.9 | 1,385 | 1,532 | 1,604 |
| Net income 1 | 823.8 | 1,556 | 2,377 | 1,279 | 418 | 995 | 1,128 | 1,213 |
| Net margin | 7.13% | 11.13% | 14.75% | 8.6% | 3.44% | 7.78% | 8.42% | 8.63% |
| EPS 2 | 8.350 | 15.88 | 24.39 | 13.97 | 4.770 | 11.64 | 13.09 | 14.56 |
| Free Cash Flow 1 | 1,044 | 1,754 | 2,649 | 1,474 | 874.1 | 1,071 | 1,308 | 1,472 |
| FCF margin | 9.04% | 12.54% | 16.43% | 9.91% | 7.19% | 8.38% | 9.76% | 10.47% |
| FCF Conversion (EBITDA) | 51.08% | 47.64% | 62.98% | 50.42% | 42.18% | 48.5% | 55.62% | 59.08% |
| FCF Conversion (Net income) | 126.79% | 112.69% | 111.44% | 115.24% | 209.11% | 107.68% | 115.97% | 121.31% |
| Dividend per Share 2 | - | - | - | - | - | 2.877 | 2.968 | 3.039 |
| Announcement Date | 2/13/20 | 2/11/21 | 2/10/22 | 2/16/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4,060 | 4,056 | 3,900 | 3,697 | 3,606 | 3,674 | 3,778 | 3,034 | 3,057 | 3,033 | 3,177 | 3,191 | 3,228 | 3,228 | 3,347 |
| EBITDA 1 | 1,001 | 997.3 | 888.4 | 748.8 | 681 | 605.5 | 590.1 | 539.6 | 514.1 | 482.1 | 547.2 | 562.3 | 565.1 | 550.6 | 584 |
| EBIT 1 | 907.1 | 902.2 | 794 | 656.1 | 589.1 | 509.9 | 493.5 | 448.3 | 423.9 | 394.9 | 452.8 | 468.2 | 465.1 | 450.8 | 492.3 |
| Operating Margin | 22.34% | 22.24% | 20.36% | 17.75% | 16.34% | 13.88% | 13.06% | 14.78% | 13.87% | 13.02% | 14.25% | 14.67% | 14.41% | 13.96% | 14.71% |
| Earnings before Tax (EBT) 1 | 768.2 | 686 | 640.1 | 476.4 | 421.6 | 44.5 | 277.8 | 205 | 238.7 | -147.1 | 297.4 | 344.6 | 350.1 | 320.5 | 378.5 |
| Net income 1 | 587.3 | 553 | 491.6 | 358.6 | 352.8 | 76.1 | 212.9 | 188.9 | 183.3 | -167.1 | 228 | 276.6 | 276.4 | 262.4 | 291.1 |
| Net margin | 14.47% | 13.63% | 12.61% | 9.7% | 9.78% | 2.07% | 5.64% | 6.23% | 6% | -5.51% | 7.18% | 8.67% | 8.56% | 8.13% | 8.7% |
| EPS 2 | 6.050 | 5.750 | 5.230 | 3.870 | 3.900 | 0.8600 | 2.390 | 2.120 | 2.110 | -1.970 | 2.690 | 3.023 | 2.981 | 2.868 | 3.240 |
| Dividend per Share 2 | - | - | - | 0.7200 | 0.7200 | - | 0.7200 | 0.7200 | - | - | 0.7360 | 0.7510 | 0.7510 | 0.7510 | 0.7638 |
| Announcement Date | 10/28/21 | 2/10/22 | 4/28/22 | 7/28/22 | 10/27/22 | 2/16/23 | 4/25/23 | 7/27/23 | 10/26/23 | 2/15/24 | 4/25/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 5,967 | 4,475 | 4,040 | 4,910 | 4,518 | 4,817 | 3,979 | 3,591 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.918 x | 1.216 x | 0.9605 x | 1.679 x | 2.18 x | 2.18 x | 1.692 x | 1.442 x |
| Free Cash Flow 1 | 1,045 | 1,754 | 2,649 | 1,474 | 874 | 1,071 | 1,308 | 1,472 |
| ROE (net income / shareholders' equity) | 15.4% | 27.7% | 28.2% | 17.9% | 13.2% | 15.3% | 15.7% | 15.8% |
| ROA (Net income/ Total Assets) | 6.53% | 12.3% | 11% | 4.5% | 6.44% | 6.85% | 7.29% | 7.79% |
| Assets 1 | 12,619 | 12,641 | 21,571 | 28,397 | 6,490 | 14,524 | 15,476 | 15,578 |
| Book Value Per Share 2 | 77.80 | 96.00 | 110.0 | 114.0 | 93.90 | 97.30 | 108.0 | 117.0 |
| Cash Flow per Share 2 | 14.70 | 21.80 | 31.90 | 21.40 | 15.20 | 18.20 | 20.50 | 23.30 |
| Capex 1 | 400 | 382 | 460 | 482 | 454 | 461 | 463 | 499 |
| Capex / Sales | 3.46% | 2.73% | 2.86% | 3.24% | 3.73% | 3.6% | 3.46% | 3.55% |
| Announcement Date | 2/13/20 | 2/11/21 | 2/10/22 | 2/16/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
198.4
USD
Average target price
240.9
USD
Spread / Average Target
+21.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.71% | 16.73B | |
| -14.92% | 84.68B | |
| +13.30% | 81.12B | |
| +10.92% | 29.4B | |
| -3.06% | 16.36B | |
| -2.63% | 14.92B | |
| -3.97% | 11.66B | |
| -1.42% | 11.72B | |
| -31.75% | 11.77B | |
| +27.44% | 11.71B |
- Stock Market
- Equities
- LH Stock
- Financials Laboratory Corporation of America Holdings
